NEW YORK, NY / ACCESSWIRE / July 27, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
Class Period: May 15, 2020 - May 22, 2020
Lead Plaintiff Deadline: July 27, 2020
The complaint alleges that throughout the class period Sorrento Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to success or safety in vivo, or in person; (ii) the Company's finding was not a "cure" for COVID-19; and (ii) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in SRNE: http://www.kleinstocklaw.com/pslra-1/sorrento-therapeutics-inc-loss-submission-form?id=8190&from=1
Chembio Diagnostics, Inc. (NASDAQ:CEMI)
Class Period: March 12, 2020 - June 16, 2020
Lead Plaintiff Deadline: August 17, 2020
According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.
Learn about your recoverable losses in CEMI: http://www.kleinstocklaw.com/pslra-1/chembio-diagnostics-inc-loss-submission-form?id=8190&from=1
J2 Global, Inc. (NASDAQ:JCOM)
Class Period: October 5, 2015 - June 29, 2020
Lead Plaintiff Deadline: September 8, 2020
The complaint alleges that during the class period J2 Global, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) J2 Global engaged in undisclosed related party transactions; (2) J2 Global used misleading accounting to hide requisite impairments and underperformance in acquisitions; (3) several so-called independent members of the Company' board of directors and audit committee were not disinterested; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Learn about your recoverable losses in JCOM: http://www.kleinstocklaw.com/pslra-1/j2-global-inc-loss-submission-form?id=8190&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm